Tritonix.ai

News / Taiwan / economic_daily

Pegavision August Revenue Jumps 18% YoY; Q3 Record High in Sight

Health Technology · Medical Specialties · economic_daily · 2026-09-02

6491

Pegavision reported August revenue of NT$750 million, driven by strong demand in Japan and the scaling of its silicone hydrogel lens production.

What Happened

Revenue Growth: Pegavision reported August consolidated revenue of NT$750 million, an 18.8% increase year-on-year, marking its second-highest monthly revenue for two consecutive months. With a 22.5% year-to-date growth, the company is well-positioned to set a new quarterly revenue record in Q3.

Market Strategy: The company is prioritizing capacity allocation for the Japanese, European, and U.S. markets to maximize profitability. While demand in China is growing, intense price competition has led Pegavision to focus its resources on higher-margin silicone hydrogel and functional lens products in other regions.

Product Mix Optimization: Growth in the second half of the year is driven by the scaling of silicone hydrogel products, including daily disposables and multifocal lenses for the Japanese and European markets. The company expects silicone hydrogel products to account for 15% of total revenue by year-end, supporting a steady recovery in gross margins.

Capacity Expansion: Pegavision’s monthly production capacity has surpassed 100 million lenses. The company is currently focusing its expansion efforts on the Daxi plant to specialize in silicone hydrogel production, which will allow the Guishan plant to optimize its output and improve overall operational efficiency.

Read original

More in Health Technology

Daewoong Pharmaceutical Shares Fall as Medytox Increases Damages Claim

Health Technology · yonhap_finance · 2026-09-03

Daewoong Pharmaceutical shares dropped early today after Medytox increased its damages claim to 500 billion KRW in their ongoing botulinum toxin dispute.

069620, 086900

Alteogen Shares Surge on $3.2 Billion Licensing Deal with Novartis

Health Technology · yonhap_finance · 2026-09-03

Alteogen's stock rose after announcing a major licensing agreement with Novartis for its proprietary subcutaneous injection technology platform, ALT-B4.

196170

Shinhan Securities Raises Alteogen Target Price Following Novartis Mega-Deal

Health Technology · yonhap_finance · 2026-09-02

Shinhan Securities has increased its target price for Alteogen to 540,000 KRW, highlighting the strategic significance of its 4.4 trillion KRW Novartis deal.

196170

Latest in Taiwan

Transmission Component Stocks Gain Momentum Amid AI and Robotics Growth

Electronic Technology · cnyes · 2026-09-03

Transmission component manufacturers like Hiwin and Hiwin Mikrosystem are gaining traction as AI and robotics demand drives growth in semiconductor equipment precision.

US Stocks Rebound Boosts Sentiment; Taiwan Market Eyes Recovery Above 5-Day Moving Average

Electronic Technology · economic_daily · 2026-09-03

Following a sharp decline in the Taiwan market, positive momentum from US tech stocks and eased interest rate concerns provide a potential path for recovery.

Analysts Raise Target Price for Jentech (3653-TW) to NT$6,725 Amid Bullish Outlook

Electronic Technology · cnyes · 2026-09-03

Following a recent FactSet survey, analysts have raised the median target price for Jentech (3653-TW) to NT$6,725, reflecting an 8.47% increase in optimism.

3653

August Revenue Update: 51 Small-Cap Taiwan Stocks Report Results

cnyes · 2026-09-02

As of September 3, 2026, 51 small-cap Taiwanese firms have released their August revenue figures, with 20 companies showing year-over-year growth exceeding 25%.

2419, 6486, 6580, 7427